PLASMODIUM AXENIC LIVER STAGES AS A NONINFECTIOUS WHOLE ORGANISM MALARIA VACCINE

• US 20100210004A1
• Filed: 01/08/2010
• Published: 08/19/2010
• Est. Priority Date: 09/04/2003
• Status: Abandoned Application

• Current Assignee: New York University
• Original Assignee: New York University
• Inventors: Camargo, Nelly, Singh, Agam P., Nussenzweig, Victor, Kaiser, Karine, Kappe, Stefan H. I.
• Application Number:
  US12/684,464
• Publication Number:
  US 20100210004A1
• Time in Patent Office: Days
• US Class Current: 435/258.200
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 39/015 Hemosporidia antigens, e.g. Plasmodium antigens
• CPC Class Codes: C07K 14/445 Plasmodium
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to the treatment and prevention of malaria infection. In particular, the present invention provides novel noninfectious, whole organism vaccines for malaria, which vaccines comprise a Plasmodium axenic liver stage. The invention also provides methods to treat and prevent malaria by administering such Plasmodium axenic liver stage vaccines, as well as methods to generate Plasmodium axenic liver stages.

Claims

1. A method for the generation of a Plasmodium falciparum axenic liver stage exoerythrocytic form (EEF), which method comprises culturing a Plasmodium falciparum sporozoite in the absence of a hepatocyte, wherein the Plasmodium sporozoite is cultured at a temperature between about 35°

C. and about 39°

C. in culture medium comprising serum and wherein the method does not require host cells.

2. The method of claim 1, wherein the temperature is about 37°

C.

3. The method of claim 1, wherein the culture medium comprises between about 5% and about 15% by volume of serum.

4. The method of claim 3, wherein the culture medium comprises about 10% by volume of serum.

5. The method of claim 1, wherein the serum is fetal bovine serum.

6. The method of claim 1, wherein the culture medium is Dulbecco'"'"'s Modified Eagle Medium (DMEM).

7. The method of claim 1, wherein the Plasmodium sporozoite is cultured at a temperature of about 37°

C. for at least about 18 hours.

8. The method of claim 7, wherein the Plasmodium sporozoite is cultured at a temperature of about 37°

C. about 24 hours.

9. The method of claim 1, wherein the Plasmodium sporozoite is cultured at a temperature between about 18°

C. and about 24°

C. for up to about 24 hours in culture medium comprising serum, and then cultured at a temperature ranging between about 35°

C. to between about 39°

C. in culture medium comprising serum.

10. The method of claim 9, wherein the Plasmodium sporozoite is cultured at a temperature of about 22°

C. for up to about 24 hours.

11. The method of claim 9, wherein the sporozoite is cultured at a temperature between about 18°

C. and about 24°

C. for about 24 hours.

12. The method of claim 9, wherein the Plasmodium sporozoite is cultured at a temperature of about 22°

C. for about 24 hours.

13-23. -23. (canceled)